cell survival assays for individualised chemotherapy in primary glioma cultures—colourmetric or luminescent细胞生存分析个性化化疗在初级神经胶质瘤cultures-colourmetric或发光.pdfVIP

Neuroscience Medicine, 2011, 2, 376-383 doi:10.4236/nm.2011.24050 Published Online December 2011 (http://www.SciRP.org/journal/nm) Cell Survival Assays for Individualised Chemotherapy in Primary Glioma Cultures— Colourmetric or Luminescent? 1* 1 1 2 Timothy P. Dawson , Katherine Ashton, Aprajay Golash , Charles H. G. Davis , R. Venkat Iyer , Phil Roberts3 3 3 , Fred Harris , Robert W. Lea 1Lancashire Teaching Hospitals NHS Trust, Preston, UK; 2Frenchay Hospital, Frenchay, Bristol, UK; 3University of Central Lanca- shire, Preston, UK. * E-mail: Timothy.Dawson@lthtr.nhs.uk Received October 13th, 2011; revised November 18th, 2011; accepted November 26th, 2011. ABSTRACT In vitro chemosensitivity testing of short term primary glioma cultures derived from brain biopsies is still in the re- search phase and has not yet found a place in clinical use. The main reasons for this slow progression are the small amounts of tissue available and the lack of a suitably sensitive assay capable of use in the clinical setting. This study examines whether the MTS and ATP cell survival assays, which determine cytotoxicity via colorimetric and lumines- cence analysis respectively, could potentially fulfill this role. Primary glioma cultures were tested for chemosensitivity using the MTS and ATP assays and were found to be generally sensitive to cisplatin and paclitaxel but relatively resis- tant to carmustine and etoposide. For both assays, LD50 values lay in the range 2 - 130 μg/ml but in the vast majority of cases, those obtained by the ATP assay were markedly lower those obtained by the MTS assay. Moreover, at cell num- bers less than 2000 in the cases of paclitaxel and carmustine and less than 4500 in the case of cisplatin, these drugs were generally indicated